SCHEMBL4920844

SCHEMBL4920844

CS(=O)(=O)Nc1cccc(Nc2nc(NCc3cccnc3)c3nc[nH]c3n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.55
CYP3A4 P08684 7/20 0.55
CYP2D6 P10635 7/20 0.55
CYP2C19 P33261 6/20 0.55
TSHR P16473 4/20 0.55
ALDH1A1 P00352 4/20 0.55
HSD17B10 Q99714 4/20 0.52
USP2 O75604 4/20 0.52
CYP2C9 P11712 4/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 2/20 0.52
HPGD P15428 2/20 0.52
MAPK1 P28482 1/20 0.52
ALOX15 P16050 2/20 0.44
PTK2 Q05397 4/20 0.43
TDP1 Q9NUW8 1/20 0.42
PDE5A O76074 2/20 0.42
VNN1 O95497 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916374 0.91 PDE5A (0.50) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL4914819 0.89 PDE5A (0.44) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL4919702 0.87 PDE5A (0.42) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL4909992 0.87 PDE5A (0.43) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL4912787 0.87 PTK2 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL4917738 0.86 MAPT (0.46) TSHRALDH1A1MAPTMAPK1PTK2
SCHEMBL4917319 0.86 PTK2 (0.45) PTK2PDE5A
SCHEMBL4917306 0.85 PTK2 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL4910563 0.85 PTK2 (0.45) MAPK1PTK2PDE5AJAK3
SCHEMBL4918965 0.85 PTK2 (0.50) CYP3A4MAPK1PTK2PDE5ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK CYP1A2 1961/4885CYP3A4 667/4885CYP2D6 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.